We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

59 hedge funds and large institutions have $29M invested in Akoya BioSciences in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

5.15% less ownership

Funds ownership: 30.23%25.08% (-5.2%)

13% less funds holding

Funds holding: 6859 (-9)

56% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 16

58% less capital invested

Capital invested by funds: $69.7M → $29M (-$40.7M)

Holders
59
Holders Change
-9
Holders Change %
-13.24%
% of All Funds
0.85%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
21
Reduced
20
Closed
16
Calls
$180K
Puts
Net Calls
+$180K
Net Calls Change
-$200K
Name Holding Trade Value Shares
Change
Change in
Stake
HighTower Advisors
26
HighTower Advisors
Illinois
$63K
Renaissance Technologies
27
Renaissance Technologies
New York
$51.9K -$90.9K -28,500 -56%
Deutsche Bank
28
Deutsche Bank
Germany
$49K -$2.6K -816 -4%
Bank of America
29
Bank of America
North Carolina
$48.3K +$35K +10,962 +113%
Ameriprise
30
Ameriprise
Minnesota
$46.1K -$48.3K -15,150 -43%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$45.3K +$61.8K +19,370 New
XT
32
XTX Topco
Cayman Islands
$44.4K -$19.6K -6,135 -24%
RIA
33
Regal Investment Advisors
Michigan
$43.9K +$23.4K +7,340 +64%
CF
34
Corebridge Financial
Texas
$33.5K +$45.6K +14,295 New
Goldman Sachs
35
Goldman Sachs
New York
$31.2K +$3.17K +993 +8%
JP Morgan Chase
36
JP Morgan Chase
New York
$27.8K -$9.02K -2,827 -19%
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$27.6K -$86 -27 -0.2%
Mirae Asset Global ETFs Holdings
38
Mirae Asset Global ETFs Holdings
Hong Kong
$26.6K +$36.3K +11,389 New
Barclays
39
Barclays
United Kingdom
$21.9K -$27.3K -8,551 -48%
Wells Fargo
40
Wells Fargo
California
$19.9K +$5.04K +1,581 +23%
UBS Group
41
UBS Group
Switzerland
$19.1K -$42.4K -13,287 -62%
Citadel Advisors
42
Citadel Advisors
Florida
$18.2K -$168K -52,826 -87%
TRCT
43
Tower Research Capital (TRC)
New York
$15.7K +$17.3K +5,414 +412%
Citigroup
44
Citigroup
New York
$13.6K +$6.16K +1,932 +50%
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
$7K +$5.61K +1,758 +169%
Legal & General Group
46
Legal & General Group
United Kingdom
$5.87K
Group One Trading
47
Group One Trading
Illinois
$4.78K -$3.03K -951 -32%
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$4.5K -$1.29K -406 -17%
SIA
49
Sit Investment Associates
Minnesota
$4K
Fidelity Investments
50
Fidelity Investments
Massachusetts
$3.34K -$3.52K -1,102 -44%

AKYA Hedge Fund Activity: Q2 2024 in Review

59 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q2 2024, worth a combined $29M — down 58% from $69.7M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AKYA and 7 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 21 added.

The largest buyer was Paragon Associates & Paragon Associates II Joint Venture, opening a new position worth an estimated $1.12M. The largest seller was Polar Capital Holdings, cutting an estimated $3.99M.

  • 59 institutional investors held Akoya BioSciences (AKYA) as of Q2 2024, down from 68 in Q1 2024.
  • Funds reported $29M of Akoya BioSciences stock for Q2 2024, down 58% quarter-over-quarter.
  • 7 funds opened new Akoya BioSciences positions in Q2 2024 and 16 closed out, a net change of -9 holders.
  • The largest Akoya BioSciences buyer in Q2 2024 was Paragon Associates & Paragon Associates II Joint Venture, an estimated $1.12M added.
  • The largest Akoya BioSciences seller in Q2 2024 was Polar Capital Holdings, an estimated $3.99M sold.

Based on aggregated 13F filings for Q2 2024.